PharmacoEconomics & Outcomes News 804, p22 - 2 Jun 2018 Nivolumab plus ipilimumab cost effective for advanced melanoma Whether or not overall survival (OS) data are used in cost-effectiveness analysis, the combination of nivolumab and ipilimumab appears to be cost effective in patients with advanced melanoma in England, according to findings of a Bristol-Myers Squibb Pharmaceuticals-funded study published in PharmacoEconomics - Open. A partitioned survival model and a Markov model were used to evaluate the cost effectiveness of nivolumab plus ipilimumab, compared with ipilimumab alone in adults with unresectable or metastatic melanoma, over a lifetime time horizon. The models were populated with 18-month progression-free survival (PFS) data or 36-month with OS data from the head-to-head, phase III CheckMate 067 trial. PFS was estimated from pre-progression survival and time to progression. Patient-level data was used to estimate post-progression survival (PPS). Based on list prices of the drugs, the models without and with OS data found similar absolute costs for nivolumab plus ipilimumab and for ipilimumab alone; total incremental costs were £11 438 and £12 084, respectively. Incremental QALY gains with combination therapy compared with ipilimumab alone were 2.54 and 2.86, respectively. In both models, nivolumab plus ipilimumab was more cost effective than ipilimumab alone, with estimated incremental cost-effectiveness ratios (ICERs) of £4225 and £4502 per QALY gained, respectively. Cost-effectiveness acceptability curves showed that nivolumab plus ipilimumab was the regimen most likely to be cost effective at willingness-to-pay thresholds of £30 000 and £50 000, per QALY gained. "Although it may lead to conservative estimates of OS, our analysis shows that for comparators with similar mechanisms of action, assuming equal PPS or using data from earlier data-cuts can go some way to overcoming this limitation, providing comparable ICERs in the absence of OS data," said the authors. * 2015 British pounds Lee D, et al. Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. PharmacoEconomics-Open : 22 May 2018. Available from: URL: https:// doi.org/10.1007/s41669-018-0080-5 803323501 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera